Vexor scores pharma catalysts across five layers of scientific and regulatory evidence — then finds where the options market is wrong.
“RAS(ON) inhibitor with compelling Phase 2 monotherapy data in PDAC. The market is underpricing the clinical signal relative to the competitive landscape.”
Does the drug actually do what the company claims?
Are the endpoints real? Is the data clean?
What has this team claimed before? Were they right?
Can they survive to the catalyst date?
Any SEC enforcement, data manipulation, or fraud signals?
| DRUG | INDICATION | DIRECTION | OUTCOME |
|---|---|---|---|
| Daraxonrasib (RVMD) | Pancreatic cancer | ↑ bullish | +38% on readout |
| Resmetirom (MDGL) | NASH fibrosis | ↑ bullish | First NASH approval |
| Belapectin (GALT) | NASH fibrosis | ↓ bearish | Trial failed |
| Simufilam (SAVA) | Alzheimer's disease | ↓ bearish | Failed + SEC fraud |
These calls were made from public documents before the outcomes resolved. No hindsight.
$500 – $1,000 / month
$25,000 – $50,000 / year
Early access is limited. The track record is public.
Request access